Citations

Showing 10 of 108119 citations.

Autoimmunity-Associated Gut Commensals Modulate Gut Permeability and Immunity in Humanized Mice
Balakrishnan, Baskar , Luckey, David, Taneja, Veena , Balakrishnan, Baskar

Mayo Clinic

Military Medicine | March 22, 2019 | Volume: 184 | Issue: Supplement_1 | Pages: 529-536

10.1093/milmed/usy309 | PMID 30901468 Get It

Abstract Objective Although the etiology of rheumatoid arthritis (RA) is unknown, recent studies have led to the concept that gut dysbiosis may be involved in onset. In this study, we aimed to determine if human gut commensals modulate the immune response and gut epithelial integrity in DQ8 mice. Methods DQ8 mice were orally gavaged with RA-associated (Eggerthella lenta or Collinsella aerofaciens) and non-associated (Prevotella histicola or Bifidobacterium sp.) on alternate days for 1 week in naïve mice. Some mice were immunized with type II collagen and oral gavage continued for 6 weeks and followed for arthritis. Epithelial integrity was done by FITC-Dextran assay. In addition, cytokines were measured in sera by ELISA and various immune cells were quantified using flow cytometry. Results Gut permeability was increased by the RA-associated bacteria and was sex and age-dependent. In vivo and in vitro observations showed that the RA-non-associated bacteria outgrow the RA-associated bacteria when gavaged or cultured together. Mice gavaged with the RA-non-associated bacteria produced lower levels of pro-inflammatory MCP-1 and MCP-3 and had lower numbers of Inflammatory monocytes CD11c+Ly6c+, when compared to controls. E. lenta treated naïve mice produce Th17 cytokines. Conclusions Our studies suggest that gut commensals influence immune response in and away from the gut by changing the gut permeability and immunity. Dysbiosis helps the growth of RA-associated bacteria and reduces the beneficial bacteria.
Importance of and strategies for achieving gender equity in hematology
Marshall, Ariela L. , Wolanskyj, Alexandra P. , Wolanskyj-Spinner, Alexandra P., Marshall, Ariela , Wolanskyj-Spinner, Alexandra P

Mayo Clinic

American Journal of Hematology | March 22, 2019 | Volume: 94 | Issue: 6 | Pages: No page available

10.1002/ajh.25468 | PMID 30900766 Get It

Disease-modifying therapies should be stopped in NMOSD patients in remission – Commentary
Wingerchuk, Dean M.

Mayo Clinic

Multiple Sclerosis Journal | March 22, 2019 | Volume: 25 | Issue: 9 | Pages: 1220-1222

10.1177/1352458519837924 | PMID 30900942 Get It

Early Versus Late Computed Tomography and Nasal Endoscopy in the Diagnosis of Nasopharyngeal and Paranasal Sinus Malignancy
Marino, Michael J. , Hsieh, Mei‐Chin , Wu, Eric , Riley, Charles A. , Wu, Xiao‐Cheng , McCoul, Edward D.

Mayo Clinic

American Journal of Rhinology & Allergy | March 22, 2019 | Volume: 33 | Issue: 4 | Pages: 388-394

10.1177/1945892419838106 | PMID 30900468 Get It

Background Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) may be associated with an increased risk of subsequent diagnosis of nasopharyngeal carcinoma (NPC) or paranasal sinus cancer (PSC) in elderly Americans. The clinical utility of this association remains uncertain. Objective To compare early computed tomography (CT) or nasal endoscopy (NE) with late diagnostic studies for the diagnosis of NPC or PSC in elderly Americans with CRS or AR. Methods The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was queried from 2003 to 2011 and included 150 088 Medicare beneficiaries. Patients with a diagnosis of CRS or AR were examined for either NE or CT performed within 6 months of the exposure diagnosis. The risk of a cancer diagnosis was determined between the early and the late diagnostic groups. Results The relative risk of early cancer diagnosis with NE was 1.98 (95% confidence interval [CI], 1.60–2.43). The number needed to detect (NND) a case of cancer with NE was 503 (95% CI, 387–718). The relative risk of an early cancer diagnosis using CT was 3.40 (95% CI, 2.85–4.06) and NND was 221 (95% CI, 194–255). The stage of NPC or PSC for the late diagnostic group was not different from those with early NE ( P = .458) or CT ( P = .497). Overall survival was not different between diagnostic groups for NE ( P = .789) or CT ( P = .425). Conclusions Early NE or CT is associated with a higher likelihood of cancer diagnosis in elderly individuals with a diagnosis of CRS or AR. The clinical utility of this association is limited due to the low prevalence of these malignancies and lack of difference in disease stage and overall survival between diagnostic groups.
Controversies, Consensus, and Collaboration in the Use of 131 I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medici
Tuttle, R. Michael , Ahuja, Sukhjeet, Avram, Anca M. , Bernet, Victor , Bourguet, P., Daniels, Gilbert H. , Dillehay, Gary, Draganescu, Ciprian, Flux, Glenn , Führer, Dagmar, Greenspan, Bennett S. , Luster, Markus , Muylle, Kristoff , Nostrand, Douglas Van , Verburg, Frederik A. , Hegedüs, László , Bernet, Victor J, Giovanella, Luca , Smit, Johannes W. A.

Mayo Clinic

Thyroid® | March 22, 2019 | Volume: 29 | Issue: 4 | Pages: 461-470

10.1089/thy.2018.0597 | PMID 30900516 Get It

Background: Publication of the 2015 American Thyroid Association (ATA) management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met with disagreement by the extended nuclear medicine community with regard to some of the recommendations related to the diagnostic and therapeutic use of radioiodine ( 131 I). Because of these concerns, the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging declined to endorse the ATA guidelines. As a result of these differences in opinion, patients and clinicians risk receiving conflicting advice with regard to several key thyroid cancer management issues. Summary: To address some of the differences in opinion and controversies associated with the therapeutic uses of 131 I in differentiated thyroid cancer constructively, the ATA, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association each sent senior leadership and subject-matter experts to a two-day interactive meeting. The goals of this first meeting were to (i) formalize the dialogue and activities between the four societies; (ii) discuss indications for 131 I adjuvant treatment; (iii) define the optimal prescribed activity of 131 I for adjuvant treatment; and (iv) clarify the definition and classification of 131 I-refractory thyroid cancer. Conclusion: By fostering an open, productive, and evidence-based discussion, the Martinique meeting restored trust, confidence, and a sense of collegiality between individuals and organizations that are committed to optimal thyroid disease management. The result of this first meeting is a set of nine principles (The Martinique Principles) that (i) describe a commitment to proactive, purposeful, and inclusive interdisciplinary cooperation; (ii) define the goals of 131 I therapy as remnant ablation, adjuvant treatment, or treatment of known disease; (iii) describe the importance of evaluating postoperative disease status and multiple other factors beyond clinicopathologic staging in 131 I therapy decision making; (iv) recognize that the optimal administered activity of 131 I adjuvant treatment cannot be definitely determined from the published literature; and (v) acknowledge that current definitions of 131 I-refractory disease are suboptimal and do not represent definitive criteria to mandate whether 131 I therapy should be recommended.
Hypokalemic periodic paralysis – the importance of patient education
Lewis, K.L. , Malouff, Timothy D. , Kesler, Alex M. , LEWIS, KRISTYN L, Harris, Dana M.

Mayo Clinic

Romanian Journal of Internal Medicine | March 22, 2019 | Volume: 57 | Issue: 3 | Pages: 263-265

10.2478/rjim-2019-0004 | PMID 30901316 Get It

Abstract Hypokalemic periodic paralysis (HOKPP) is a rare neuromuscular disorder caused by altered transport of cellular potassium that leads to significant muscle weakness of the extremities. Paralytic attacks are induced by a drop in the serum potassium level and they have been associated with specific triggers. This case describes a 21-year-old male who has had recurrent presentations of acute paralytic attacks following vigorous physical activity. At presentation, this patient exhibited flaccid paralysis of all skeletal muscles below the neck, but was alert and oriented with stable vital signs. The patient was found to have a potassium level of 2.1 mmol/L and an EKG demonstrating U waves (characteristic of hypokalemia). The patient was treated with potassium supplementation with resolution of symptoms. The mainstay of prevention of long term permanent muscle weakness is avoidance of triggers that can lead to hypokalemia. Through education on disease process and lifestyle modifications, we were able to end the cycle of recurrent hospital readmissions and the subsequent financial burden this generated for the patient and his family.
Penile Prosthesis Infection: Myths and Realities
Hebert, Kevin , Köhler, Tobias S. , Hebert, Kevin J

Mayo Clinic

The World Journal of Men's Health | March 22, 2019 | Volume: 37 | Issue: 3 | Pages: 276

10.5534/wjmh.180123 | PMID 30929326 Get It

Staging of T1 esophageal adenocarcinoma with volumetric laser endomicroscopy: a feasibility study
Kamboj, Amrit K. , Muppa, Prasuna, Sawas, Tarek , Lutzke, Lori S., Buras, Matthew , Golafshar, Michael A. , Katzka, David A. , Iyer, Prasad G. , Smyrk, Thomas C. , Wang, Kenneth T. , Kahn, Allon , Leggett, Cadman L. , Buras, Matthew R , Golafshar, Michael

Mayo Clinic

Endoscopy International Open | March 22, 2019 | Volume: 07 | Issue: 04 | Pages: E462-E470

10.1055/a-0838-5326 | PMID 30931378 Get It

Abstract Background and study aims Precise staging in T1 esophageal adenocarcinoma (EAC) is critical in determining candidacy for curative endoscopic resection. High-frequency endoscopic ultrasound (EUS) has demonstrated suboptimal accuracy in T1 EAC staging due to insufficient spatial resolution. Volumetric laser endomicroscopy (VLE) allows for high-resolution wide-field visualization of the esophageal microstructure. We aimed to investigate the role of VLE in staging T1 EAC. Patients and methods Patients undergoing endoscopic mucosal resection (EMR) were prospectively enrolled and only T1 EAC cases were included. EMR specimens were imaged using second-generation VLE immediately after resection. VLE images were analyzed for signal intensity by depth and signal attenuation (dB/mm) in both cross-sectional and en-face orientation. A decision tree model was constructed to combine measured VLE parameters and delineate diagnostic thresholds. Results Thirty EMR scans were obtained – 15 T1a specimens from 9 patients and 15 T1b specimens from 11 patients. T1b specimen VLE scans exhibited higher signal intensity (P < 0.0001) and higher signal attenuation compared to T1a specimens (P = 0.03). A combination of signal attenuation and signal intensity at 150 µm depth yielded optimal diagnostic thresholds and an area under the curve (AUC) of 0.77. VLE signal attenuation was significantly associated with grade of differentiation, irrespective of EAC stage. Conclusions VLE signal intensity and signal attenuation are quantitatively distinct in T1a and T1b EAC and associated with grade of differentiation. This is the first study examining the role of VLE for staging of T1 EAC and demonstrates promising diagnostic performance. With further in vivo validation, VLE may serve a role in staging superficial EAC.
Central Roles of OX40L–OX40 Interaction in the Induction and Progression of Human T Cell–Driven Acute Graft-versus-Host Disease
Tripathi, Trivendra , Yin, Wenjie , Xue, Yaming, Zurawski, Sandra , Fujita, Haruyuki, Hanabuchi, Shino , Oh, SangKon, Joo, HyeMee , Yin, Wenjie , Liu, Yong-Jun

Mayo Clinic

ImmunoHorizons | March 21, 2019 | Volume: 3 | Issue: 3 | Pages: 110-120

10.4049/immunohorizons.1900001 | PMID 31240276 Get It

Abstract Graft-versus-host disease (GVHD) is one of the major obstacles for the success of allogeneic hematopoietic stem cell transplantation. In this article, we report that the interaction between OX40L and OX40 is of critical importance for both induction and progression of acute GVHD (aGVHD) driven by human T cells. Anti-human OX40L mAb (hOX40L) treatment could thus effectively reduce the disease severity in a xenogeneic-aGVHD model in both preventative and therapeutic modes. Mechanistically, blocking OX40L–OX40 interaction with an anti-hOX40L reduces infiltration of human T cells in target organs, including liver, gut, lung, and skin. It also decreases IL-21– and TNF-producing T cell responses while promoting regulatory T cell responses without compromising the cytolytic activity of CD8+ T cells. Single blockade of hOX40L was thus more effective than dual blockade of IL-21 and TNF in reducing the severity of aGVHD as well as mortality. Data from this study indicate that OX40L–OX40 interactions play a central role in the pathogenesis of aGVHD induced by human T cells. Therapeutic strategies that can efficiently interrupt OX40L–OX40 interaction in patients might have potential to provide patients with an improved clinical benefit.
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
Leonard, John P. , Izutsu, Koji , Fowler, Nathan , Hong, Xiaonan, Zhu, Jun , Zhang, Huilai , Offner, Fritz , Scheliga, Adriana , Nowakowski, Grzegorz S. , Pinto, Antonio , Fogliatto, Laura Maria , Moreira, Cláudia, Cabeçadas, José , Kalambakas, Stacey, Fustier, Pierre , Wu, Chengqing , Investigators, for the AUGMENT Trial, Izutsu, Koji , Trněný, Marek , Re, Francesca, Scheinberg, Phillip , Flinn, Ian W. , Liu, David , Gribben, John G. , Investigators, for the AUGMENT Trial, Pinto, Antonio

Mayo Clinic

Journal of Clinical Oncology | March 21, 2019 | Volume: 37 | Issue: 14 | Pages: 1188-1199

10.1200/jco.19.00010 | PMID 30897038 Get It

PURPOSEPatients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase the activity of rituximab.METHODSA phase III, multicenter, randomized trial of lenalidomide plus rituximab versus placebo plus rituximab was conducted in patients with relapsed and/or refractory follicular or marginal zone lymphoma. Patients received lenalidomide or placebo for 12 cycles plus rituximab once per week for 4 weeks in cycle 1 and day 1 of cycles 2 through 5. The primary end point was progression-free survival per independent radiology review.RESULTSA total of 358 patients were randomly assigned to lenalidomide plus rituximab (n = 178) or placebo plus rituximab (n = 180). Infections (63% v 49%), neutropenia (58% v 23%), and cutaneous reactions (32% v 12%) were more common with lenalidomide plus rituximab. Grade 3 or 4 neutropenia (50% v 13%) and leukopenia (7% v 2%) were higher with lenalidomide plus rituximab; no other grade 3 or 4 adverse event differed by 5% or more between groups. Progression-free survival was significantly improved for lenalidomide plus rituximab versus placebo plus rituximab, with a hazard ratio of 0.46 (95% CI, 0.34 to 0.62; P < .001) and median duration of 39.4 months (95% CI, 22.9 months to not reached) versus 14.1 months (95% CI, 11.4 to 16.7 months), respectively.CONCLUSIONLenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile.